Accolade Inc (ACCD)

$9.17

+0.47

(+5.4%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Accolade Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 93.22M → 99.37M (in $), with an average increase of 3.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -38.40M → -21.06M (in $), with an average increase of 36.4% per quarter

  • Vs HQY

    In the last 1 year, Healthequity Inc has given 37.0% return, outperforming this stock by 78.0%

  • Vs HQY

    In the last 3 years, Healthequity Inc has given 12.5% return, outperforming this stock by 94.3%

Performance

  • $8.70
    $9.33
    $9.17
    downward going graph

    5.14%

    Downside

    Day's Volatility :6.77%

    Upside

    1.71%

    downward going graph
  • $6.33
    $17.01
    $9.17
    downward going graph

    30.97%

    Downside

    52 Weeks Volatility :62.79%

    Upside

    46.09%

    downward going graph

Returns

PeriodAccolade IncSector (Health Care)Index (Russel 2000)
3 Months
-26.77%
-0.7%
0.0%
6 Months
27.01%
6.6%
0.0%
1 Year
-41.02%
3.7%
-1.5%
3 Years
-81.07%
14.0%
-21.8%

Highlights

Market Capitalization
650.2M
Book Value
$5.65
Earnings Per Share (EPS)
-1.62
Wall Street Target Price
15.07
Profit Margin
-31.59%
Operating Margin TTM
-32.08%
Return On Assets TTM
-9.7%
Return On Equity TTM
-26.66%
Revenue TTM
388.5M
Revenue Per Share TTM
5.24
Quarterly Revenue Growth YOY
9.3%
Gross Profit TTM
165.3M
EBITDA
-88.6M
Diluted Eps TTM
-1.62
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.21
EPS Estimate Next Year
-1.07
EPS Estimate Current Quarter
-0.44
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    76%Buy
    23%Hold
    0
    0%Sell
Based on 21 Wall street analysts offering stock ratings for Accolade Inc(by analysts ranked 0 to 5 stars)
Based on 21 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
16
Hold
5
5
7
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 64.34%

Current $9.17
Target $15.07

Company Financials

FY18Y/Y Change
Revenue
76.8M
-
Net Income
-61.3M
-
Net Profit Margin
-79.77%
-
FY19Y/Y Change
Revenue
94.8M
↑ 23.41%
Net Income
-56.5M
↓ 7.82%
Net Profit Margin
-59.59%
↑ 20.18%
FY20Y/Y Change
Revenue
132.5M
↑ 39.76%
Net Income
-51.4M
↓ 9.08%
Net Profit Margin
-38.76%
↑ 20.83%
FY21Y/Y Change
Revenue
170.4M
↑ 28.57%
Net Income
-50.7M
↓ 1.39%
Net Profit Margin
-29.73%
↑ 9.03%
FY22Y/Y Change
Revenue
310.0M
↑ 81.98%
Net Income
-123.1M
↑ 143.08%
Net Profit Margin
-39.71%
↓ 9.98%
FY23Y/Y Change
Revenue
363.1M
↑ 17.13%
Net Income
-459.7M
↑ 273.32%
Net Profit Margin
-126.58%
↓ 86.87%
Q3 FY22Q/Q Change
Revenue
87.6M
↑ 2.47%
Net Income
-46.5M
↓ 86.43%
Net Profit Margin
-53.08%
↑ 347.75%
Q4 FY22Q/Q Change
Revenue
90.9M
↑ 3.77%
Net Income
-39.9M
↓ 14.3%
Net Profit Margin
-43.84%
↑ 9.24%
Q1 FY23Q/Q Change
Revenue
99.0M
↑ 8.88%
Net Income
-30.4M
↓ 23.67%
Net Profit Margin
-30.73%
↑ 13.11%
Q2 FY23Q/Q Change
Revenue
93.2M
↓ 5.86%
Net Income
-38.4M
↑ 26.21%
Net Profit Margin
-41.2%
↓ 10.47%
Q3 FY23Q/Q Change
Revenue
96.9M
↑ 3.9%
Net Income
-32.8M
↓ 14.54%
Net Profit Margin
-33.89%
↑ 7.31%
Q4 FY23Q/Q Change
Revenue
99.4M
↑ 2.59%
Net Income
-21.1M
↓ 35.83%
Net Profit Margin
-21.2%
↑ 12.69%
FY18Y/Y Change
Total Assets
47.1M
-
Total Liabilities
230.8M
-
FY19Y/Y Change
Total Assets
65.8M
↑ 39.68%
Total Liabilities
296.4M
↑ 28.43%
FY20Y/Y Change
Total Assets
124.4M
↑ 89.19%
Total Liabilities
148.2M
↓ 50.0%
FY21Y/Y Change
Total Assets
475.5M
↑ 282.2%
Total Liabilities
84.7M
↓ 42.87%
FY22Y/Y Change
Total Assets
1.3B
↑ 170.35%
Total Liabilities
429.7M
↑ 407.59%
FY23Y/Y Change
Total Assets
903.1M
↓ 29.75%
Total Liabilities
429.3M
↓ 0.11%
Q3 FY22Q/Q Change
Total Assets
931.7M
↓ 1.35%
Total Liabilities
425.4M
↑ 3.76%
Q4 FY22Q/Q Change
Total Assets
913.8M
↓ 1.92%
Total Liabilities
427.8M
↑ 0.58%
Q1 FY23Q/Q Change
Total Assets
903.1M
↓ 1.17%
Total Liabilities
429.3M
↑ 0.34%
Q2 FY23Q/Q Change
Total Assets
875.7M
↓ 3.03%
Total Liabilities
421.5M
↓ 1.81%
Q3 FY23Q/Q Change
Total Assets
854.3M
↓ 2.44%
Total Liabilities
416.7M
↓ 1.15%
Q4 FY23Q/Q Change
Total Assets
785.5M
↓ 8.06%
Total Liabilities
350.8M
↓ 15.82%
FY18Y/Y Change
Operating Cash Flow
-38.3M
-
Investing Cash Flow
-7.2M
-
Financing Cash Flow
15.0M
-
FY19Y/Y Change
Operating Cash Flow
-16.5M
↓ 56.78%
Investing Cash Flow
-3.1M
↓ 56.41%
Financing Cash Flow
48.8M
↑ 224.71%
FY20Y/Y Change
Operating Cash Flow
-34.2M
↑ 106.96%
Investing Cash Flow
-3.5M
↑ 12.92%
Financing Cash Flow
28.2M
↓ 42.21%
FY21Y/Y Change
Operating Cash Flow
-25.2M
↓ 26.32%
Investing Cash Flow
-2.4M
↓ 31.18%
Financing Cash Flow
428.4M
↑ 1417.91%
FY22Y/Y Change
Operating Cash Flow
-62.4M
↑ 147.11%
Investing Cash Flow
-263.6M
↑ 10779.61%
Financing Cash Flow
257.9M
↓ 39.79%
FY23Y/Y Change
Operating Cash Flow
-40.7M
↓ 34.72%
Investing Cash Flow
-7.2M
↓ 97.26%
Financing Cash Flow
3.2M
↓ 98.77%
Q3 FY22Q/Q Change
Operating Cash Flow
-3.0M
↓ 90.17%
Investing Cash Flow
-1.6M
↑ 28.3%
Financing Cash Flow
-370.0K
↓ 124.54%
Q4 FY22Q/Q Change
Operating Cash Flow
-4.7M
↑ 56.77%
Investing Cash Flow
-1.9M
↑ 17.1%
Financing Cash Flow
1.6M
↓ 534.32%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.6M
↓ 45.46%
Investing Cash Flow
-2.4M
↑ 26.27%
Financing Cash Flow
418.0K
↓ 73.99%
Q2 FY23Q/Q Change
Operating Cash Flow
-19.3M
↑ 653.69%
Investing Cash Flow
-3.3M
↑ 36.18%
Financing Cash Flow
4.5M
↑ 964.83%
Q3 FY23Q/Q Change
Operating Cash Flow
-8.0M
↓ 58.32%
Investing Cash Flow
-3.3M
↑ 0.0%
Financing Cash Flow
641.0K
↓ 85.6%

Technicals Summary

Sell

Neutral

Buy

Accolade Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Accolade Inc
Accolade Inc
-8.71%
27.01%
-41.02%
-81.07%
-70.71%
Solventum Corp
Solventum Corp
-10.64%
-10.64%
-10.64%
-10.64%
-10.64%
Veeva Systems Inc.
Veeva Systems Inc.
-12.8%
-3.39%
8.83%
-26.33%
55.83%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
-5.98%
30.6%
1.83%
40.83%
40.83%
Healthequity Inc
Healthequity Inc
-3.72%
6.22%
37.05%
12.91%
23.47%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Accolade Inc
Accolade Inc
NA
NA
NA
-1.21
-0.27
-0.1
NA
5.65
Solventum Corp
Solventum Corp
NA
NA
NA
0.0
0.12
0.08
NA
NA
Veeva Systems Inc.
Veeva Systems Inc.
62.03
62.03
1.35
4.76
0.13
0.05
NA
28.8
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
28.08
28.08
20.11
4.3
0.19
0.06
0.0
15.67
Healthequity Inc
Healthequity Inc
125.42
125.42
2.29
2.19
0.03
0.03
NA
23.63
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Accolade Inc
Accolade Inc
Buy
$650.2M
-70.71%
NA
-31.59%
Solventum Corp
Solventum Corp
NA
$11.7B
-10.64%
NA
16.42%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$32.3B
55.83%
62.03
22.24%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$39.0B
40.83%
28.08
8.02%
Healthequity Inc
Healthequity Inc
Buy
$6.9B
23.47%
125.42
5.57%

Institutional Holdings

  • ARK Investment Management LLC

    8.79%

  • JPMorgan Chase & Co

    8.28%

  • Brown Advisory Holdings Inc

    7.70%

  • BlackRock Inc

    7.31%

  • Vanguard Group Inc

    6.88%

  • Bellevue Group AG

    5.82%

Corporate Announcements

  • Accolade Inc Earnings

    Accolade Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

accolade is a personalized health and benefits solution that dramatically improves the experience, outcomes and cost of healthcare for employers, health plans and their members. with a unique blend of compassionate advisors, clinical experts and intelligent technologies, we engage individuals and families in their health, establish trust, and influence their decisions at every stage of care. we’ve been recognized as one of the nation’s 25 most promising companies by forbes magazine, the fastest-growing private healthcare company by inc. 500, and a top workplace by multiple news publications. for more information, visit www.accolade.com.

Organization
Accolade Inc
Employees
2370
CEO
Mr. Rajeev Singh
Industry
Health Services

Discover More

FAQs